Dupilumab Improves Quality of Life and Symptoms in Eosinophilic Esophagitis
A recent study from the LIBERTY EoE TREET trial demonstrates that dupilumab significantly improves health-related quality of life (HRQoL), dysphagia perception, and symptoms beyond dysphagia in patients with eosinophilic esophagitis (EoE). These findings, published in The American Journal of Gastroenterology, underscore the potential of dupilumab as an effective treatment for adults and adolescents (≥12 years) with EoE.
The study assessed the impact of weekly dupilumab 300 mg compared to placebo using the EoE Symptom Questionnaire (EoE-SQ), EoE Impact Questionnaire, and Patient Global Impression tools. At week 24, patients receiving dupilumab reported significant improvements in EoE-SQ frequency scores in both parts A (least squares mean difference vs placebo −1.7; P < 0.01) and B (−1.4; P < 0.01). Severity scores were also reduced in part A (−2.0; P < 0.05) and trended positively in part B (−1.5; P = 0.07).
“These improvements were clinically meaningful to patients, reducing the frequency and severity of symptoms beyond dysphagia,” the authors noted.
HRQoL scores improved significantly, particularly in areas such as emotional well-being and sleep disturbance, as measured by the EoE Impact Questionnaire. Dupilumab-treated patients were more likely to report improvements in the Patient Global Impression of Change of dysphagia compared to placebo and were more likely to report no symptoms of dysphagia at week 24.
“Dupilumab reduced the impact of EoE on multiple aspects of HRQoL and patients' impression of dysphagia,” the study concluded.
This evidence highlights dupilumab’s broad efficacy in addressing the symptomatic and quality-of-life burdens of EoE, offering clinicians a valuable option for managing this challenging condition.
Reference
Spergel JM, Chehade M, Dellon ES, et al. Dupilumab improves health-related quality of life and a range of symptoms in patients with eosinophilic esophagitis. Am J Gastroenterol. 2024;119(12):2398-2407. doi:10.14309/ajg.0000000000002924
